文章预览
SITC的报道不一定更新很及时，完全看心情，有意思的讲几句，没意思的就看看图，反正也不吃亏 Novel Single-Agent Immunotherapies (268) A phase 1 study of retifanlimab (INCMGA00012), a PD-1 inhibitor, in patients with advanced solid tumors: preliminary results in recurrent MSI-high or dMMR endometrial cancer (POD1UM-101) INCMGA00012用于MSI-H或者MMR的子宫内膜癌的治疗，其他PD-X历史数据ORR 26.7-57.1%， INCMGA00012 的ORR 33.3%（8/24） (355) First-in-human phase I study of NKTR-255 in patients with relapsed/refractory hematologic malignancies https://www.nektar.com/application/files/2416/0496/2658/Shah_et_al._NKTR-255_Poster_SITC_2020_Final.pdf NKTR-255属于能够促进IL-15Rα/IL2Rβγ复合物形成扩增NK细胞，促进CD8+ T细胞的增殖、活化，但不会激活Treg细胞，能够形成长期的免疫记忆 。由于N
………………………………
